RSV: we finally have a vaccine for this deadly virus

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration.

Metadata
Provider: 
The ConversationThe Conversation
URL: 
https://theconversation.com/rsv-we-finally-have-a-vaccine-for-this-deadly-virus-205145https://theconversation.com/rsv-we-finally-have-a-vaccine-for-this-deadly-virus-205145
Retrieved on: 
Tuesday, May 9, 2023
Information
Tags: 
People, Vaccine, European Medicines Agency data breach, Volunteering, GSK plc, US Food Sovereignty Alliance, F, Mumps, Clinical trial, Brain, Cough, Cell, Inflammation, Palivizumab, Respiratory syncytial virus, Measles, Paralysis, Death, RSV, Guillain, Effectiveness, Sneeze, European Medicines Agency, Virus, Pneumonia
Geotags: 
UK
Summary
Key Points: 
  • The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration.
  • The European Medicines Agency is recommending the use of this vaccine, with a final decision likely to be made in July 2023.
  • Eventually, a key part of the virus, called F protein was identified as a likely vaccine target.
  • The Arexvy vaccine, developed by the UK-based pharmaceutical company GlaxoSmithKline, is known as a “protein subunit vaccine”.
Copyright: 
2023 The Conversation. All Rights Reserved.